Abstract: A cosmetic composition is shown for rejuvenating the appearance of skin with reduced or minimal potential for skin irritation, in the form of a lotion or cream which includes as a major component aloe vera as well as vitamins A, B, C, D and E.

Abstract: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds which are modulators of Retinoid X Receptors.

Abstract: The present invention relates to a novel retinol derivative and a cosmetic composition comprising the same, in particular, to a novel retinol derivative represented by the formula (I) exhibiting the effects from both L-ascorbic acid and retinol as well as being free from the disadvantages of two compounds such as skin irritation and instability in cosmetic formulation, and a cosmetic composition comprising the retinol derivative.

Abstract: A method for treating anorectal disorders, comprising a step of providing a suppository containing between 1000 and 500,000 IU of an antioxidant selected from the group of Vitamin A, Vitamin C, Vitamin E; and a step of placing the suppository within the rectal cavity for a period of time required for dissolution of the suppository.

Abstract: The present invention provides compositions and methods for lowering plasma Lp(a) levels in humans. The present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol, LDL-cholesterol, triglycerides and other metabolic risk factors.

Abstract: Non-toxic, naturally derived and economical compositions for treating and preventing bacterial or fungal disease in plants, especially citrus canker, wherein such compositions include various combinations of d-limonene, wax and monohydric alcohol are provided. Methods for making and using such compositions are also provided.

Abstract: The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.

Abstract: The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of ?-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

Abstract: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing during this period or for general application and to enable the person receiving the nutritional supplementation to achieve maximum healing and rapid recovery from a procedure or injury.

Abstract: A formulation for enteral administration to a patient is disclosed.

Abstract: The present invention relates to ascorbic acid single-phase solution compositions that provide enhanced stability, enhanced solubility and an enhanced photoprotective effect as compared to prior compositions. The compositions comprise L-ascorbic acid; a cinnamic acid derivative such as p-coumaric acid, ferulic acid, caffeic acid, sinapinic acid, a derivative thereof, and a combination thereof; a solvent comprising a glycol ether and an alkanediol; and water; the composition having a pH of no more than about 3.5. The compositions may also comprise a form of Vitamin E and are useful for treatment of radical-induced damage to a subject, particularly the skin of a subject.

Abstract: A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.

Abstract: UVB radiation of about 300-310 nm wavelength and UVA radiation of about 380-390 nm wavelength, each of which exists in solar light, induces MMPs (matrix metalloproteinases) in human skin that degrade the collagen of the dermal matrix. This degradation contributes to photoaging of human skin, which can be prevented by blocking these wavelengths of solar radiation. In contrast, diseases that result in the overproduction of collagen can be treated by exposing the affected with to radiation having wavelengths in those regions, for these wavelengths not only induce MMPs but also inhibit collagen biosynthesis. For lighter skinned people so affected, the UVA wavelengths are preferred because of the reduced amount of erythema, whereas dark skinned people can be treated with the UVB radiation because they generally do not suffer from erythema.

Abstract: Exposure of human skin to ultraviolet (UV) radiation from the sun not only induces the production of enzymes (matrix metalloproteinases) that degrade collagen, but also inhibits the synthesis of new collagen by inhibiting the synthesis of procollagen. This UV-induced inhibition of the synthesis of collagen can be prevented by the topical application of a retinoid or c-JUN inhibitor to the skin prior to exposure to UV radiation.

Abstract: This invention features fractionated oxidized carotenoid or retinoid mixtures, and individual components thereof, which are useful as cell-differentiation-inducing, anti-proliferative, anti-metastatic and anti-tumor agents. The mixtures and compounds of the invention can be used alone or in combination with other anticancer agents for the treatment of cancer.

Abstract: The present invention relates to a process for crystallizing small particles with a narrow particle size distribution. The crystals of the invention are obtained by introducing ultrasound into a solution or suspension of the substance to be crystallized while simultaneously adjusting a particular specific stirring power.

Abstract: A topical medicament, and associate method of use, for the treatment of dermatologic conditions in both humans and animals is provided. The medicament includes a mixture of Vitamin A, Vitamin D, Vitamin E, lanolin, petroleum jelly, colloidal silver, ti tree oil, zinc oxide and corn starch in appropriate proportions. Ingredient proportions may be varied to form an ointment or a paste having a thicker consistency than the ointment.

Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.

Abstract: External skin preparations containing one or more members selected from among a fermentation product, which is obtained by treating a bean extract with a microorganism, vitamin A and its derivatives. By potentiating skin cells and accelerating the production of hyaluronic acid, these preparations exert effects of preventing and relieving skin roughness, improving keratin, moistening, and preventing and relieving skin tension failure and wrinkles, thereby efficaciously retarding skin aging.

Abstract: A water-dispersible vitamin composition containing Vitamins A, D3 or E, or a precursor thereof, an alkyl lactate and an emulsifier and is substantially free of water.

Abstract: Mixed zeaxanthin C8–C20 carboxylic acid esters in which the mixed zeaxanthin esters constitute about 50 mg/g or more of the concentrate and wherein the zeaxanthin is about 20 percent or more of the total carotenoids present when assayed after saponification are disclosed, as are the products that can be made from such a concentrate, as well as the several uses for mixed zeaxanthin esters.

Abstract: A method of inhibiting the expression of inflammatory cytokines and chemokines in an animal or man, is disclosed. The method comprises administration to said animal or man of at least one type of xanthophyll, e.g. astaxanthin, in an amount inhibiting the expression of inflammatory cytokines and chemokines in said animal or man. Use of at least one type of xanthophyll, such as astaxanthin, for the preparation of a medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines in an animal or man, is described. Further, a commercial package containing a medicament comprising at least one type of xanthophyll, e.g. astaxanthin, and written and/or data carrier instructions for administration to an animal or man of the medicament for the prophylactic and/or therapeutic inhibition of the express of inflammatory cytokines and chemokines, is disclosed.

Abstract: Rosacea is treated with a composition comprising an antimicrobial and at least one of an anti-inflammatory and a non-retinoid inhibitor of at least one of NF-??, AP-1, MMPs, adhesion molecules, TLRs, and CD14. The composition may further comprise a retinoid.

Abstract: There is provided a topical composition and method for improving the aesthetic appearance of skin, particularly, preventing, ameliorating, treating and/or reducing fine lines and/or wrinkles, without the skin irritation typically associated with topical application of a retinoid. There is also provided a topical composition and method for improving the aesthetic appearance of lips, particularly decreasing the number and/or depth of vertical lip lines. The composition has an effective amount of retinoxytrimethylsilane. Preferably, the composition is applied daily to skin and/or lips. The composition and method are particularly suitable for persons having sensitive skin.

Abstract: The invention describes a means for the treatment of diseases of the tracheo-bronchial tract, particularly of COPD.

Abstract: Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife and convenient dispensing and application are provided.

Abstract: An improved soft gelatin formulation and process methodology that increases single Coenzyme Q10 molecules presented to the absorption channels of the small intestines by providing medium chain triglycerides, Vitamin E and natural beta carotene to Coenzyme Q10 in a soft gel capsule to increase the absorption thereof.

Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.

Abstract: The present invention provides methods of effecting a change in the core circadian clock by modulating retinoid nuclear receptors.

Abstract: The present invention is based on a novel method for encapsulating in liposomes substantially water immiscible carotenoids. Therefore, there are provided by the present invention formulations comprising liposomes loaded with an amount of at least one water immiscible carotenoid, pharmaceutical compositions comprising such a formulation, and a method for preparing the liposomes loaded with said carotenoid.

Abstract: A composition of biochemical substances for the treatment of arrhythmia in a human susceptible to arrhythmia, and its method of administration, comprising at least one ascorbate compound selected from the group consisting of ascorbic acid, pharmaceutically acceptable ascorbate salts and/or mixtures thereof in combination with at least one carnitine compound selected from the group of carnitine hydrochloride, pharmaceutically acceptable carnitine salts and/or mixtures thereof.

Abstract: Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation and damage to the liver cells. Typically, steatohepatitis involves inflammation of the liver related to fat accumulation, and mimics alcoholic hepatitis but is observed in patients who seldom or never consume alcohol. Nonalcoholic steatohepatitis can lead to serious liver damage, and ultimately cirrhosis. The present invention provides methods and compositions useful for the treatment or alleviation of nonalcoholic steatohepatitis and the pharmaceutical formulations for their administration to a human. Specifically, compositions comprised of lecithin, antioxidants and vitamin B complex are administered parenterally, most preferably by oral administration. Specific therapeutic formulations include admixtures of these compounds and specific dosage formulations include daily oral administrations of these compounds in tablet or powder forms.

Abstract: A composition and method is provided for promoting weight loss in a mammal by feeding effective amounts of at least three nutrients selected from L-carnitine, chromium, Vitamin A, and a source of carbohydrates selected from a low glycemic index grain. The composition preferably includes all four nutrients and may be fed in an amount of 1.0 to 10.0 mg of L-carnitine per kilogram of body weight per day, from about 5.0 to about 15.0 micrograms of chromium per kilogram of body weight per day, and from about 1.0 to 3.0 grams of starch per kilogram of body weight per day.

Abstract: The present invention refers to a process, a composition and the use of Vitamin C for enhancing the action of Vitamin A on the cellular activity of an individual. According to the invention, the association of Vitamin C to Vitamin A will be applied to said individual at a weight ratio ranging from 1:1 to about 10:1.

Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney

Abstract: A stable skin care composition containing about 0.0001% to about 50% of at least one retinoid booster, about 0.001% to about 10% of a retinoid; and a cosmetically acceptable vehicle, wherein the stable skin care composition is contained in a package so that the composition is out of contact with oxygen.

Abstract: The present invention provides therapeutic compositions containing lysophosphatidic acids, methods for making the compositions, and methods of use thereof.

Abstract: Compositions and methods are provided for ameliorating various effects of UVA and UVB radiation from the sun. The compositions include an ingredient that prevents photoaging from MED and subMED radiation, namely a direct acting MMP (matrix metalloproteinase) inhibitor. The compositions can include another, indirect MMP inhibitor, such as a retinoid, certain other compounds (such as N-acetylcysteine, 2-furildioxime, and vitamin C), tetracyclines, and if a retinoid is used then in addition optional compounds that inhibit the CYP-26 (chytochrome P-450) mediated metabolism of retinoids such as ketoconazole and other azole compounds. In the method, the composition is applied prior to exposure to the sun; for direct acting MMP inhibitors, application should be just prior to exposure, and if indirect inhibitors such as retinoids are used in addition, then application of the indirect inhibitor should be at least about seven hours prior to exposure.

Abstract: Chronological aging of human skin can be delayed with the topical application of an MMP inhibitor, preferably a retinoid (an indirect MMP inhbitor); retinoids also normalize procollagen biosynthesis. Chronological aging, or natural aging, is evidenced in elderly (80+ years old) skin by increased MMP levels and decreased procollagen levels when compared with younger individuals. Prophylactic treatment of not yet chronologically-aged skin with a retinoid both inhibits degradation of dermal collagen and restores procollagen synthesis. Biopsied sections from elderly skin show that a single treatment of chronologically-aged skin with a retinoid can increase epidermal thickness, improve the dermal collagen density, and promote the formation of rete pegs and dermal papillae. Such benefits are helpful in preventing bruising, tearing, and ulceration of elderly skin. Accordingly, prophylactic treatment begun much earlier in life with an MMP inhibitor and/or a retinoid delays the onset of such symptoms.

Abstract: The present invention concerns stabilized cosmetic material containing triple-encapsulated retinol. Unstable, fat-soluble retinol is stabilized firstly by addition into vesicles consisting of nonionic surface-active agent, cholesterol and cholesteryl ester. The firstly stabilized retinol(vesicle) is subsequently inserted into sphingosomes (a kind of multi lamellar liposome) consisting of lecithin and ceramide. Finally the double-encapsulated retinol (sphingosome) is inserted into lamellar liquid-crystal emulsifying base, thereby being triply encapsulated.

Abstract: The perioperative multivitamin protein bar for promoting an anabolic state in a person is made of from about 250 mg to about 2500 mg of a digestive enzyme, such as bromelain, pepsin, amylase, protease, lipase, cellulase, lactase, alpha-g, glucoamylase, invertase, malt diastase, pectinase, xylanase, bromelain, betain, trypsin, or combinations thereof; from about 50 mg to about 2500 mg of an amino acid; from about 200 mg to about 2000 mg of a sea plant; from about 10 mg to about 8000 mg of a flavoring; from about 100 mg to about 2500 mg of Vitamin A, Vitamin B, Vitamin D, Vitamin E, Vitamin K, calcium, complexes thereof, or combinations thereof; and from about 1000 mg to about 9000 mg of a fiber.

Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.

Abstract: A clear aqueous formulation for topical application in the oral cavity of humans to treat leukoplakia contains water, ?-carotene, a water miscible polyol, an unsaturated fatty acid ester, and a surfactant, preferably polyethoxylated castor oil or POE(20) sorbitan monooleate. The formulation preferably also contains a pharmaceutically acceptable anti-oxidant, preferably d-alpha-tocopherol (vitamin E), and is in the form of an oral rinse or as a gel well suited for spreading on gums or other parts of the oral cavity. The formulation is applied in a gel form on a substantially regular daily basis to areas in the oral cavity where leukoplakia lesions are present. Persistent application of the gel results in substantial diminution or total elimination of the leukoplakia lesions.

Abstract: Disclosed herein are systemic formulations comprising beta-carotene and a solubilizer selected from tetrahydrofuran (THF), polyethylene glycol (PEG), and mixtures thereof. Generally, the formulations are administered to animals in need thereof in therapeutically effective amounts of beta-carotene for the purpose intended. The solubilizers greatly enhance the bioavailability of beta-carotene administered systemically. Another embodiment of the present invention is a method for administering beta-carotene to an animal in need thereof by administering the formulation of the present invention. Yet another embodiment is a method for treating an animal in need thereof by administering a therapeutically effective amount of the formulation of the present invention. The invention includes a method for treating an animal suffering from or susceptible to sepsis by administering an effective amount for treating sepsis of the formulation of the present invention.

Abstract: A wiping article is provided which includes an effervescent cleanser composition held within a pouch formed from a first and second substrate sheet. At least one of the substrate sheets must be water permeable. The effervescent composition is an intimate mixture of an acid material such as citric acid and an alkaline material such as sodium bicarbonate. Water contact causes the combination to effervesce. A dry surfactant such as sodium cocoyl isethionate in contact with the water and effervescing carbon dioxide results in a highly pleasant sudsing system. Skin benefit agents may be included within the composition. The effervescent action may improve deposition of the skin benefit agents onto the skin.

Abstract: A fat composition for oral or enteral administration which contains eicosapentaenoic acid and/or a derivative thereof, docosahexaenoic acid and/or a derivative thereof, and a C20 or higher monoenoic acid and/or a derivative thereof and functions to diminish hexacosanoic acid; and a hexacosanoic acid depressant which comprises as active ingredients eicosapentaenoic acid and/or a derivative thereof, docosahexaenoic acid and/or a derivative thereof, and a C20 or higher monoenoic acid and/or a derivative thereof. They can be prepared by extraction from a fish oil or the like, purification, blending, etc. Based on the function of diminishing hexacosanoic acid, the composition and the depressant produce an aging-inhibitory effect on cell membranes, which is effective in the prevention and treatment of lifestyle-related diseases.

Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.

Abstract: A water-in-oil (W/O) emulsion with a discontinuous aqueous phase dispersed in a continuous oil phase has in the continuous oil phase a linear silicone polyether, an ?,?-diene crosslinked silicone elastomer, and a nonionic organic emulsifier. The W/O emulsion is otherwise free of silicone elastomers prepared using unsaturated compounds containing silicon atoms. Either the discontinuous aqueous phase of the W/O emulsion or the continuous oil phase of the W/O emulsion contains a water soluble or oil soluble active ingredient such as a vitamin.

Abstract: A neuroprotective composition for protecting neuronal cells against oxidative stress and methods for using and preparing the same. More particularly, the neuroprotective composition of the invention comprises a mixture of pyruvate, antioxidant, and lipid(s) such as fatty acids. The neuroprotective composition could be used for the treatment of brain trauma, brain or cerebrovascular ischemia, neurodegenerative diseases, poisoning of neuronal cells, the diminution of drugs side effects and for preservation of neuronal grafts.

Abstract: Skin care compositions comprising a water-in-oil emulsion base containing retinoids and possessing good physical and chemical stability.